Reuters Right Now
Starbucks faces fresh questions over its avoidance of tax in Europe, but Reuters correspondent Tom Bergin says politicians have only themselves to blame if they leave loopholes for companies to exploit. Tom Bergin’s story on Starbucks can be read here.
Austerity budgets and competition from cheap generics are forcing big drugmakers to get creative about pricing – and that’s making an already fragmented European drugs market even more opaque, says Reuters European pharmaceuticals correspondent Ben Hirschler. Ben Hirschler’s full report on big pharma’s pricing tactics can be read here.